Aerosol Inhalation Treatment for Dyspnea - Patients

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this protocol is to develop and test aerosol furosemide, as a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Collaborator: National Institute of Nursing Research (NINR)
• Treatments: Furosemide

Criteria

Inclusion Criteria:

• Intractable dyspnea at rest or with minimal activity

Exclusion Criteria:

• Chronic congestive heart failure

• Liver or kidney disease

• Systemic lupus erythematosis (SLE)

• Receiving potassium supplementation or other indication of hypokalemia

• Major psychiatric disorders

• Furosemide hypersensitivity

• Not mentally competent and/or alert (unable to grant informed consent)

• Under 18 years old

• Not fluent in English

• Inadequate birth control